Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Return on Equity (2020 - 2025)

Avidity Biosciences' Return on Equity history spans 6 years, with the latest figure at 0.38% for Q4 2025.

  • For Q4 2025, Return on Equity fell 16.0% year-over-year to 0.38%; the TTM value through Dec 2025 reached 0.38%, down 16.0%, while the annual FY2025 figure was 0.44%, 10.0% down from the prior year.
  • Return on Equity reached 0.38% in Q4 2025 per RNA's latest filing, down from 0.36% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.21% in Q3 2024 to a low of 0.43% in Q3 2022.
  • Average Return on Equity over 5 years is 0.32%, with a median of 0.34% recorded in 2022.
  • Peak YoY movement for Return on Equity: crashed -62bps in 2021, then grew 20bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.3% in 2021, then decreased by -20bps to 0.36% in 2022, then decreased by -14bps to 0.42% in 2023, then soared by 47bps to 0.22% in 2024, then crashed by -74bps to 0.38% in 2025.
  • Per Business Quant, the three most recent readings for RNA's Return on Equity are 0.38% (Q4 2025), 0.36% (Q3 2025), and 0.36% (Q2 2025).